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Summary  Antimicrobial  resistance  in  bacterial  pathogens  is  a  challenge  that  is
associated  with  high  morbidity  and  mortality.  Multidrug  resistance  patterns  in  Gram-
positive  and  -negative  bacteria  are  difﬁcult  to  treat  and  may  even  be  untreatable
with  conventional  antibiotics.  There  is  currently  a  shortage  of  effective  therapies,
lack  of  successful  prevention  measures,  and  only  a  few  new  antibiotics,  which
require  development  of  novel  treatment  options  and  alternative  antimicrobial  ther-
apies.  Bioﬁlms  are  involved  in  multidrug  resistance  and  can  present  challenges  for
infection  control.  Virulence,  Staphylococcus  aureus,  Clostridium  difﬁcile  infection,
vancomycin-resistant  enterococci,  and  control  in  the  Emergency  Department  are
also  discussed.
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Antibiotic resistance
This  study  discusses  the  impact  of antibiotic  resis-
tance as  a  persistent,  global  health  threat  and
highlights  efforts  to  improve  this  complex  problem
[1].  Political  agendas,  legislation,  development  of
therapies and  educational  initiatives  are  essential
to mitigate  the  increasing  rate  of  antibiotic  resis-
tance.  Prescribers,  policymakers  and  researchers
are charged  with  the  complex  task  of  mitigating
antibiotic resistance  in  an  era  when  new  treat-
ments for  bacterial  infections  are  limited.  The
authors  propose  that  monitoring,  surveillance  of
practice,  policy  and  new  treatments  provide  solu-
tions to  antibiotic  resistance  in  both  the  human  and
agricultural  sectors.  This  article  emphasizes  the
complexity  of  antibiotic  resistance  and  highlights
the need  for  a  multifaceted  approach  to  improve
health care  outcomes  [1].
Antimicrobial  resistance  in  bacterial  pathogens
is a  worldwide  challenge  associated  with  high
morbidity and  mortality  [2]. Multidrug  resistant
patterns in  Gram-positive  and  -negative  bacteria
have resulted  in  difﬁcult-to-treat  or  even  untreat-
able infections  with  conventional  antimicrobials.
Because the  early  identiﬁcation  of  causative
microorganisms  and  their  antimicrobial  susceptibil-
ity patterns  in  patients  with  bacteremia  and  other
serious  infections  is  lacking  in  many  healthcare
settings, broad  spectrum  antibiotics  are  liber-
ally and  mostly  unnecessarily  used  [2].  Dramatic
increases in  emerging  resistance  occurs  and,  when
coupled  with  poor  infection  control  practices,  resis-
tant bacteria  can  easily  be  disseminated  to  the
other patients  and  the  environment  [2]. Availability
of updated  epidemiological  data  on  antimicro-
bial resistance  in  frequently  encountered  bacterial
pathogens will  be  useful  not  only  for  deciding
on treatment  strategies  but  also  for  devising  an
effective  antimicrobial  stewardship  program  in  hos-Please  cite  this  article  in  press  as:  Frieri  M,  et  al.  A
http://dx.doi.org/10.1016/j.jiph.2016.08.007
pitals [2].
Resistance  of  important  bacterial  pathogens  to
common  antimicrobial  therapies  and  emergence
of multidrug-resistant  bacteria  are  increasing  at
t
e
vn  alarming  rate.  There  are  challenges  in  the
ombat of  bacterial  infections  and  accompanied
iseases and  the  current  shortage  of  effective
rugs, lack  of  successful  prevention  measures
nd only  a few  new  antibiotics  in  the  clinical
ipeline will  require  the  development  of  novel
reatment options  and  alternative  antimicrobial
herapies [3].  The  authors  stated  that  increas-
ng understanding  of  bacterial  virulence  strategies
nd induced  molecular  pathways  of  the  infec-
ious disease  provides  novel  opportunities  to  target
nd interfere  with  crucial  pathogenicity  factors  or
irulence-associated  traits  of  the  bacteria  while
ypassing  the  evolutionary  pressure  on  the  bac-
erium to  develop  resistance  [3].  The  authors  took
 closer  look  at  the  bacterial  virulence-related  fac-
ors and  processes  that  present  promising  targets
or anti-virulence  therapies,  recently  discovered
nhibitory substances,  their  promises  and  discussed
he challenges  and  problems  that  need  to  be
aced [3].
Finding strategies  against  the  development  of
ntibiotic  resistance  is  a major  global  challenge
or the  life  sciences  community  and  for  public
ealth. The  past  decades  have  seen  a  dramatic
orldwide increase  in  human-pathogenic  bacteria
hat are  resistant  to  one  or  multiple  antibiotics
4]. More  infections  caused  by  resistant  microorgan-
sms fail  to  respond  to  conventional  treatment,  and
ven last-resort  antibiotics  have  lost  their  power.
n addition,  industry  pipelines  for  the  develop-
ent of  novel  antibiotics  have  run  dry  over  the
ast few  decades.  A  recent  World  Health  Day  by
he WHO  with  the  theme  ‘‘Combat  drug  resis-
ance: no  action  today  means  no  cure  tomorrow’’
riggered an  increase  in  research  activity,  and  sev-
ral promising  strategies  have  been  developed  to
estore treatment  options  against  infections  by
esistant  bacterial  pathogens  [4].
The  emergence  and  spread  of  antibiotic  resis-
ance among  pathogenic  bacteria  has  been  a
rowing  problem  for  public  health  in  recent
ecades. It  is  becoming  increasingly  recognizedntibiotic  resistance.  J  Infect  Public  Health  (2016),
hat not  only  antibiotic  resistance  genes  (ARGs)
ncountered in  clinical  pathogens  are  of  rele-
ance, but  rather,  all  pathogenic,  commensal  as
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ntibiotic  resistance  
ell  as  environmental  bacteria,  mobile  genetic
lements and  bacteriophages,  form  a  reservoir
f ARGs  (the  resistome)  from  which  pathogenic
acteria can  acquire  resistance  via  horizontal  gene
ransfer (HGT)  [5]. HGT  has  caused  antibiotic
esistance to  spread  from  commensal  and  environ-
ental species  to  pathogenic  ones,  as  has  been
hown for  some  clinically  important  ARGs.  While
ransformation  and  transduction  are  deemed  less
mportant,  recent  discoveries  suggest  their  role
ay be  larger  than  previously  thought.  Under-
tanding the  extent  of  the  resistome  and  how  its
obilization  to  pathogenic  bacteria  takes  place  is
ssential for  efforts  to  control  the  dissemination  of
hese genes.  The  authors  discussed  the  concept  of
he resistome,  providing  examples  of  HGT  of  clini-
ally relevant  ARGs  and  an  overview  of  the  current
nowledge of  the  contributions  the  various  HGT
echanisms  make  to  the  spread  of  antibiotic  resis-
ance [5].
Multidrug-resistant  bacteria  have  increased  at
n alarming  rate  over  recent  decades  and  cause
erious problems  [6]. The  emergence  of  resistant
nfections caused  by  these  bacteria  has  led  to  mor-
ality and  morbidity  and  there  is  an  urgent  need  to
nd solutions  to  combat  bacterial  resistance  [6]. In
his paper,  the  authors  discuss  some  mechanisms  of
ntibiotic resistance  such  as  changing  the  antibac-
erial agent’s  uptake  and  bioﬁlm  formation  as  well
s a  wide  range  of  approaches  such  as  developing
ew generations  of  antibiotics,  combination  ther-
py, natural  antibacterial  substances  and  applying
anoparticulate  systems  [6].
In this  study,  the  authors  assessed  the  propen-
ity of  biocide  exposure  in  the  development  of
acterial  antimicrobial  resistance  [7].  Their  proto-
ol was  based  on  reporting  changes  in  established
ntimicrobial  susceptibility  proﬁles  in  biocides
nd antibiotics  during  and  after  exposure  to  a
roduct.  Their  results  showed  that  exposure  to  tri-
losan (0.0004%)  was  associated  with  a high  risk
f developing  resistance  and  cross-resistance  in
taphylococcus  aureus  and  Escherichia  coli  but
as not  observed  with  exposure  to  chlorhexi-
ine (0.00005%)  or  a  hydrogen  peroxide-based
iocidal  product  (in  during  use  conditions)  [7].
xposure to  a  low  concentration  of  hydrogen  per-
xide (0.001%)  carried  a  risk  of  emerging  resistance
o antibiotics  if  the  presence  of  the  oxidizing
gent was  maintained.  They  observed  a  number
f unstable  clinical  resistances  to  antibiotics  after
xposure to  the  cationic  biocide  and  oxidizingPlease  cite  this  article  in  press  as:  Frieri  M,  et  al.  A
http://dx.doi.org/10.1016/j.jiph.2016.08.007
gent, notably  to  tobramycin  and  ticarcillin-
lavulanic acid.  Using  a  decision  tree  based  on
he change  in  antimicrobial  susceptibility  test
esults,  they  were  able  to  provide  information
P
t
a
r PRESS
3
n  the  effect  of biocide  exposure  on  the  devel-
pment of  bacterial  resistance  to  antimicrobials
7]. Thus,  such  information  should  address  the
all from  the  U.S.  FDA  and  European  Union  Bio-
idal Products  Regulation  for  manufacturers  to
rovide information  on  antimicrobial  resistance  and
ross-resistance  in  bacteria  after  the  use  of  their
roduct  [7].
ioﬁlms
athogenic  microbial  bioﬁlm  is  considered  a  world-
ide challenge  due  to  the  inherent  antibiotic
esistance conferred  by  its  lifestyle  [8]. By  living
n a community  in  a  clinical  situation,  microbial
rganisms are  responsible  for  severe  and  danger-
us cases  of  infection.  Combating  this  organization
f cells  usually  requires  high  antibiotic  doses  for  a
rolonged time,  and  these  approaches  often  fail,
ontributing  to  infection  persistence  [8]. In  addi-
ion to  therapeutic  limitations,  bioﬁlms  can  be
 source  of  infections  when  they  grow  in  med-
cal devices.  The  challenge  imposed  by  bioﬁlms
as mobilized  researchers  in  the  entire  world
o propose  or  develop  alternatives  to  control
ioﬁlms. The  authors  in  this  review  summarized
he new  frontiers  that  could  be  used  in  clinical
ircumstances to  prevent  or  eliminate  pathogenic
ioﬁlms [8].
The  treatment  of  bioﬁlm  infections  with  antibi-
tics remains  a puzzle  although  progress  on  bioﬁlm
esearch  has  been  made.  Past  pharmacokinetic  (PK)
nd pharmacodynamic  (PD)  proﬁles  of  an  antimicro-
ial agent  provide  important  information  helping
o establish  an  efﬁcient  dosing  regimen  and  to
inimize  the  development  of  antimicrobial  toler-
nce and  resistance  in  bioﬁlm  infections  [9].  Most
revious  PK/PD  studies  of  antibiotics  have  been
erformed  on  planktonic  cells,  and  extrapolation
f the  results  on  bioﬁlms  is  problematic  as  bacterial
ioﬁlms differ  from  planktonic  grown  cells  in  terms
f growth  rate,  gene  expression,  and  metabolism.
hese authors  set  up  several  protocols  for  the  stud-
es of  PK/PD  of  antibiotics  in  bioﬁlm  infections  of
seudomonas  aeruginosa  in  vitro  and  in  vivo.  It
hould be  underscored  that  none  of  the  protocols
n bioﬁlms  have  yet  been  certiﬁcated  for  clinical
se or  proved  useful  for  guidance  of  antibiotic  ther-
py [9].
The increase  in  multi-drug  resistant  P.  aeruginosa
nfections is  a worldwide  dilemma.  At  the  heart  of
he problem  is  the  inability  to  treat  establishedntibiotic  resistance.  J  Infect  Public  Health  (2016),
. aeruginosa  bioﬁlms  with  standard  antibiotic
herapy, including  ﬂuoroquinolones  [10]. These
uthors  addressed  a  previously  unstudied  question
egarding  the  effect  of  the  commonly  prescribed
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4  
calcium  channel  blocker  (CCB)  diltiazem  on  bioﬁlm
growth.  Real-time  monitoring  of  the  overall  growth
and killing  of  P.  aeruginosa  bioﬁlm  during  ﬂuoro-
quinolone therapy  in  the  presence  and  absence  of
diltiazem was  performed.  The  authors  found  that
for P.  aeruginosa  bioﬁlms,  resistance  to  ﬁrst-line
ﬂuoroquinolones  may  be  induced  by  the  commonly
prescribed calcium  channel  blocker  diltiazem  [10].
The conventional  in  vitro  models  simulate  phar-
macodynamics  of  antibiotics  in  the  treatment  of
planktonic  P.  aeruginosa. In  this  study,  the  authors
proposed  a  novel  pharmacodynamic  model  of
oﬂoxacin  activity  in  the  treatment  of  P.  aeruginosa
bioﬁlm [11].
Samples  from  the  coupons  and  the  central
compartment  bioreactor  (CCB)  were  assessed  for
viability of  the  bioﬁlm  and  shedding  planktonic  cells
over 24  h.  Oﬂoxacin  concentrations  were  assessed
in each  sample  withdrawn  for  the  CCB  using  a  bioas-
say method  [11].
The  microbiological  outcomes  on  P.  aeruginosa
bioﬁlm and  the  shedding  planktonic  cells  in
response to  different  oﬂoxacin  dosing  regimens
were not  parallel  and  this  may  explain  the
non-coincidence  of  microbiological  and  clinical  out-
comes with  bioﬁlm-associated  infections  [11].
The current  study  introduced  an  unprecedented
novel dynamic  model  for  the  assessment  of  the
microbiological  outcome  on  both  bioﬁlm  and  shed-
ding planktonic  cells  of  P.  aeruginosa  in  response
to different  dosing  regimens  of  oﬂoxacin,  which,  in
turn, can  simulate  the  clinical  outcomes  in  bioﬁlm-
associated  infections  of  P.  aeruginosa, e.g.,  cystic
ﬁbrosis.  Different  scenarios  of  antibiotic  dosing
regimens  against  bioﬁlm-related  infections  can  be
mimicked using  such  a  model  [11].
Bioﬁlms  also  occur  in  chronic  rhinosinusitis
(CRS), which  is  a  highly  prevalent  disease  in  the
adult and  pediatric  population;  it  causes  a signiﬁ-
cant burden  and  the  management  is  considered  one
of the  most  costly  public  health  expenditures  [12].
Comorbidities  include  asthma,  aspirin  sensitivity,
and nasal  polyposis.  S.  aureus  bioﬁlms  and  exotox-
ins that  act  as  super-antigens  have  been  implicated
to play  an  important  pathological  role  in  the  inci-
dence,  maintenance,  and  ongoing  burden  of  CRS.  A
better understanding  of  the  interplay  between  bac-
terial factors,  host  factors,  and  the  environment
will facilitate  better  management  of  this  disease.
This literature  review  focused  on  these  factors  and
highlighted  current  research  in  this  ﬁeld  [12].
In recent  years,  the  number  of  multidrug-Please  cite  this  article  in  press  as:  Frieri  M,  et  al.  A
http://dx.doi.org/10.1016/j.jiph.2016.08.007
resistant  bacteria  has  increased  rapidly  and  several
epidemics  were  identiﬁed  in  different  regions
of the  world.  Faced  with  this  situation  that
presents a major  global  public  health  concern,
l
b
n
b PRESS
M.  Frieri  et  al.
he  development  and  the  use  of  new  and  rapid
echnologies is  critical  [13]. The  use  of  the  next-
eneration  sequencing  platforms  by  microbiologists
nd infectious  disease  specialists  has  allowed
reat progress  in  the  medical  ﬁeld.  These  authors
eviewed the  usefulness  of  whole-genome  sequenc-
ng for  the  detection  of  virulence  and  antibiotic
esistance-associated  genes  [13].
The importance  of  bacterial  bioﬁlms  in  chronic
ound pathogenesis  is  well  established.  Different
reatment modalities,  including  topical  dressings,
ave yet  to  show  consistent  efﬁcacy  against  wound
ioﬁlms.  This  study  evaluated  the  impact  of a
ovel, antimicrobial  test  dressing  on  P.  aeruginosa
ioﬁlm-infected wounds.  Six-mm  dermal  punch
ounds  in  rabbit  ears  were  inoculated  with  10(6)
olony-forming  units  of  P.  aeruginosa  [14].  Bioﬁlm
as established  in  vivo  using  our  published  model.
ressing  changes  were  performed  every  other  day
ith either  active  control  or  test  dressings.  Treated
nd untreated  wounds  were  harvested  for  sev-
ral quantitative  endpoints.  Conﬁrmatory  studies
ere performed  to  measure  treatment  impact  on
n vitro  P. aeruginosa  and  in  vivo  polybacterial
ounds containing  P.  aeruginosa  and  S.  aureus.  The
est dressing  consistently  decreased  P. aeruginosa
acterial counts  and  improved  wound  healing  com-
ared to  inactive  vehicle  and  active  control  wounds
p <  0.05).  In  vitro  bacterial  counts  were  also  sig-
iﬁcantly  reduced  following  test  dressing  therapy
p <  0.05).  Similarly,  improvements  in  bacterial  bur-
en and  wound  healing  were  also  achieved  in
olybacterial  wounds  (p  <  0.05).  This  study  rep-
esented  the  ﬁrst  quantiﬁable  and  consistent
n vivo  evidence  of  a topical  antimicrobial  dress-
ng’s impact  against  established  wound  bioﬁlm.
he development  of  clinically  applicable  therapies
gainst  bioﬁlm  such  as  this  is  critical  to  improving
hronic wound  care  [14].
Bacteria survive  in  nature  by  forming  bioﬁlms
n surfaces  and  probably  most,  if  not  all,  bacte-
ia (and  fungi)  are  capable  of  forming  bioﬁlms.
 bioﬁlm  is  a structured  consortium  of  bacteria
mbedded in  a  self-produced  polymer  matrix  con-
isting of  polysaccharide,  protein  and  extracellular
NA. Bacterial  bioﬁlms  are  resistant  to  antibi-
tics, disinfectant  chemicals  and  to  phagocytosis
nd other  components  of  the  innate  and  adap-
ive inﬂammatory  defense  system  of  the  body  [15].
t is  known,  for  example,  that  the  persistence  of
taphylococcal  infections  related  to  foreign  bodies
s due  to  bioﬁlm  formation.  Chronic  P. aeruginosantibiotic  resistance.  J  Infect  Public  Health  (2016),
ung infections  in  cystic  ﬁbrosis  patients  are  caused
y bioﬁlm-growing  mucoid  strains.  Gradients  of
utrients and  oxygen  exist  from  the  top  to  the
ottom of  bioﬁlms  and  the  bacterial  cells  located
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ntibiotic  resistance  
n  nutrient  poor  areas  have  decreased  metabolic
ctivity and  increased  doubling  times.  These  more
r less  dormant  cells  are  therefore  responsible  for
ome of  the  tolerance  to  antibiotics.  Bioﬁlm  growth
s associated  with  an  increased  level  of  muta-
ions. Bacteria  in  bioﬁlms  communicate  by  means  of
olecules, which  activates  certain  genes  responsi-
le for  production  of  virulence  factors  and,  to  some
xtent,  bioﬁlm  structure  [15].  This  phenomenon
s called  quorum  sensing  and  depends  upon  the
oncentration  of  the  quorum-sensing  molecules  in
 certain  niche,  which  depends  on  the  number
f the  bacteria.  Bioﬁlms  can  be  prevented  by
ntibiotic prophylaxis  or  early  aggressive  antibi-
tic therapy  and  they  can  be  treated  by  chronic
uppressive antibiotic  therapy.  Promising  strategies
ay include  the  use  of  compounds  that  can  dissolve
he bioﬁlm  matrix  and  quorum-sensing  inhibitors,
hich increases  bioﬁlm  susceptibility  to  antibiotics
nd phagocytosis  [15].
Acinetobacter  baumannii, a  Gram-negative,
pportunistic  pathogen  can  form  bioﬁlm  and
ncreasing resistance  to  antibiotic  agents  presents
hallenges  for  infection  control  [16]. A  better
nderstanding of  the  inﬂuence  of  bioﬁlm  forma-
ion and  antibiotic  resistance  on  environmental
ersistence  of  A.  baumannii  in  hospital  settings
s needed  for  more  effective  infection  control
16].  These  authors  studied  high  bioﬁlm  forming,
linical,  multidrug-resistant-(MDR)-positive  strains.
nvironmental,  MDR-positive,  low  bioﬁlm  forming
trains  had  a  2.7  times  increase  in  risk  of  cell
eath due  to  desiccation  compared  with  their
DR-negative counterparts.  MDR-negative,  high
ioﬁlm-forming  environmental  strains  had  a 60%
ecrease  in  risk  compared  with  their  low  bioﬁlm-
orming counterparts.  The  MDR-positive  phenotype
as deleterious  for  environmental  strains  and  the
igh bioﬁlm  phenotype  was  critical  for  survival.
his study  provided  evidence  of  the  trade-off
etween antibiotic  resistance  and  desiccation
olerance, driven  by  condition-dependent  adap-
ation, and  establishes  rationale  for  research
nto the  genetic  basis  of  the  variation  in  ﬁt-
ess cost  between  clinical  and  environmental
solates [16].
In  this  study,  an  interdisciplinary  team  imple-
ented a  screening  program  targeting  patients  with
 history  of  methicillin-resistant  S.  aureus  (MRSA)
o reduce  unnecessary  contact  isolation  [17]. After
onverting  from  a  2-step  culture-based  protocol  to
ingle polymerase  chain  reaction  (PCR)  testing,  the
uthors increased  the  efﬁciency  of  the  screening
rogram from  77%  to  100%.  Despite  the  higher  costPlease  cite  this  article  in  press  as:  Frieri  M,  et  al.  A
http://dx.doi.org/10.1016/j.jiph.2016.08.007
f PCR-based  testing,  this  program  remained  cost-
aving [17].
a
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irulence and S. aureus
.  aureus  is  an  opportunistic  pathogen  and  the
eading cause  of  a wide  range  of  severe  clinical
nfections. The  range  of  diseases  reﬂects  the  diver-
ity of  virulence  factors  produced  by  this  pathogen
18]. To  establish  an  infection  in  the  host,  S.  aureus
xpresses  an  inclusive  set  of  virulence  factors  such
s toxins,  enzymes,  adhesins,  and  other  surface
roteins that  allow  the  pathogen  to  survive  under
xtreme  conditions  and  are  essential  for  the  bacte-
ia’s ability  to  spread  through  tissues.  Expression
nd secretion  of  this  array  of  toxins  and  enzymes
re tightly  controlled  by  a number  of  regulatory
ystems. S.  aureus  is  also  notorious  for  its  abil-
ty to  resist  the  arsenal  of  currently  available
ntibiotics and  dissemination  of various  multidrug-
esistant S.  aureus  clones  limits  therapeutic  options
or a S.  aureus  infection.  The  development  of  anti-
irulence  therapeutics  that  neutralize  S.  aureus
oxins or  block  the  pathways  that  regulate  toxin
roduction  has  shown  potential  in  thwarting  the
acteria’s  acquisition  of  antibiotic  resistance.  In
his review,  these  authors  provided  insights  into  the
egulation of  S.  aureus  toxin  production  and  poten-
ial anti-virulence  strategies  that  target  S.  aureus
oxins [18].
Successful  methicillin-resistant  S.  aureus  (MRSA)
lones  have  evolved  to  adapt  to  healthcare  and
nvironments  such  as  the  community  and  in  live-
tock.  The  authors  reviewed  recent  studies  on  clone
daptation  and  the  importance  of  genes  acquired
uring  horizontal  gene  transfer  to  survival  in  spe-
iﬁc environments  [19]. The  review  also  discussed
he role  of  global  regulators  controlling  virulence
ene expression  and  resistance  to  antibiotics,  such
s the  agr  and  vraRS  systems.  The  authors  stated
hat understanding  these  processes  in  successful
lones could  reveal  novel  targets  for  therapeutic
gents, which  are  urgently  required  to  reduce  the
nfection  burden  and  improve  treatment  options
19]. The  effect  of  decolonization  on  the  control
f methicillin-resistant  S.  aureus  (MRSA)  may  differ
epending  on  intensive  care  unit  (ICU)  settings  and
he prevalence  of  antiseptic  resistance  in  MRSA.
Community-associated  methicillin-resistant  S.
ureus (CA-MRSA)  is  a prevalent  cause  of  skin
nd soft  tissue  infections  (SSTI),  but  the  associa-
ion between  CA-MRSA  colonization  and  infection
emains uncertain.  These  authors  studied  the  car-
iage frequency  at  several  body  sites  and  the
iversity of  S.  aureus  strains  from  patients  withntibiotic  resistance.  J  Infect  Public  Health  (2016),
 closed  skin  abscess  (i.e.,  without  drainage)  and
atched  control  subjects  without  a skin  infection
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presenting  to  10  U.S.  Emergency  Departments  were
cultured  using  broth  enrichment;  wound  specimens
were cultured  from  abscess  cases.  Methicillin  resis-
tance testing  and  spa  typing  were  performed  for
all S.  aureus  isolates.  S.  aureus  was  found  in
57.8% of  abscesses;  49  isolates  were  MRSA,  and  36
were methicillin-susceptible  S.  aureus  (MSSA)  [20].
S. aureus-infected  subjects  were  usually  (75/85)
colonized with  the  infecting  strain;  among  MRSA-
infected  subjects,  colonization  was  most  common
in the  groin.  The  CC8  lineage  accounted  for  most
of both  infecting  and  colonizing  isolates,  although
more than  16  distinct  strains  were  identiﬁed.  Nearly
all MRSA  infections  were  inferred  to  be  USA300.
There was  more  diversity  among  colonizing  than
infecting  isolates  and  among  those  isolated  from
controls  versus  cases.  Detection  of  S.  aureus  col-
onization,  and  especially  MRSA,  may  be  enhanced
by extranasal  site  culture  [20].
This  study  was  conducted  in  a 14-bed  surgi-
cal ICU  over  a  40-month  period.  The  baseline
period featured  active  surveillance  for  MRSA  and
the institution  of  contact  precautions.  MRSA  decol-
onization  via  chlorhexidine  baths  and  intranasal
mupirocin was  implemented  during  a subsequent
20-month intervention  period  [21].  Both  pre-post
and  interrupted  time  series  analyses  were  used
to evaluate  changes  in  the  clinical  incidence  of
hospital-acquired  MRSA  colonization  or  infection.
MRSA  isolates  were  tested  for  the  presence  of
qacA/B genes  and  mupirocin  resistance.
In  pre—post  analysis,  the  clinical  incidence
of MRSA  signiﬁcantly  decreased  by  61.6%  after
implementation of  decolonization  (p  < 0.001)  [21].
Interrupted time  series  analysis  showed  decreases
in both  the  level  and  trend  of  clinical  MRSA
incidence. Of  169  MRSA  isolates,  64  carried  the
qacA/B genes,  and  22  showed  a  high  level  of
resistance to  mupirocin.  Low-level  mupirocin  resis-
tance signiﬁcantly  increased  from  0—19.4%  during
the study  period.  These  authors  felt  that  although
decolonization using  antiseptic  agents  was  help-
ful in  decreasing  hospital-acquired  MRSA  rates,  the
emergence  of  antiseptic  resistance  should  be  mon-
itored [21].
Current approaches  to  antibiotic  susceptibil-
ity testing  of  cultured  pathogens  have  several
limitations ranging  from  long  run  times  to  depend-
ence  on  prior  knowledge  of  genetic  mechanisms
of resistance.  These  authors  developed  a  rapid
antimicrobial  susceptibility  assay  for  S.  aureus
based on  bacterial  cytological  proﬁling,  which  usesPlease  cite  this  article  in  press  as:  Frieri  M,  et  al.  A
http://dx.doi.org/10.1016/j.jiph.2016.08.007
quantitative  ﬂuorescence  microscopy  to  measure
antibiotic-induced  changes  in  cellular  architecture
[22].  Thus,  bacterial  cytological  proﬁling  provides
a rapid  and  ﬂexible  alternative  to  gene-based
a
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usceptibility  testing  methods  for  S.  aureus,  and
hould be  readily  adaptable  to  different  antibiotics
nd bacterial  species  as  new  mechanisms  of  resis-
ance or  multidrug-resistant  pathogens  evolve  and
ppear in  clinical  practice  [22].
Healthcare  workers  may  acquire  methicillin-
esistant S.  aureus  (MRSA)  from  patients,  both
ospital  and  home  environments,  other  health-
are workers,  family  and  public  acquaintances,  and
ets [23]. There  is  a  consensus  of  case  reports
nd series  that  now  strongly  support  the  role  for
RSA-carrying  healthcare  personnel  to  serve  as  a
eservoir and  as  a  vehicle  of  spread  within  health-
are settings.  Carriage  may  occur  at a number  of
ody sites  and  for  short,  intermediate,  and  long
erms. A  number  of  approaches  have  been  taken  to
nterrupt  the  linkage  of  staff-patient  spread,  but
ost emphasis  has  been  placed  on  handwashing
nd the  treatment  of staff  MRSA  carriers  [23].  The
mportance  of  healthcare  workers  in  transmission
as been  viewed  with  varying  degrees  of  interest,
nd several  logistical  problems  have  arisen  when
ealthcare  worker  screening  is  brought  to  the  fore-
ront. There  is  now  considerable  support  for  the
creening  and  treatment  of  healthcare  workers,
ut it  is  suggested  that  the  intensity  of  any  such
pproach  must  consider  available  resources,  the
ature of  the  outbreak,  and  the  strength  of  the
pidemiological  associations.  The  task  of  assessing
ealthcare  personnel  carriage  in  any  context  should
e shaped  with  due  regard  to  national  and  interna-
ional guidelines,  should  be  honed  and  practiced
ccording to  local  needs  and  experience,  and  must
e patient-oriented  [23].
S. aureus  is  an  important  human  pathogen,
esponsible for  infections  in  the  community
nd healthcare  settings.  Although  much  of  the
ttention  is  focused  on  the  methicillin-resistant
‘variant’’  MRSA,  its  methicillin-susceptible  coun-
erpart (MSSA)  remains  a  prime  species  in  infections
24]. S.  aureus  epidemiology,  especially  that  of
RSA, has  evolved  rapidly  in  recent  years.  First  rep-
esenting  a typical  nosocomial  multidrug-resistant
athogen,  MRSA  has  recently  emerged  in  the  com-
unity and  among  farmed  animals  due  to  its
bility to  evolve  and  adapt  to  different  settings.
lobal surveillance  has  shown  that  MRSA  repre-
ents a problem  in  all  continents  and  countries,
ith an  increase  in  mortality  and  the  need  for
xpensive last-resource  antibiotics.  S. aureus  can
asily acquire  resistance  to  antibiotics  and  MRSA  is
haracteristically  multidrug  resistant  [24].  Newerntibiotic  resistance.  J  Infect  Public  Health  (2016),
nti-staphylococcal  drugs  have  been  developed,
ut because  their  clinical  use  has  been  very  limited
o far,  little  is known  about  the  emergence  of  resis-
ance.  Molecular  typing  techniques  have  allowed
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ntibiotic  resistance  
dentiﬁcation  of  the  major  successful  clones  and
ineages  of  MSSA  and  MRSA,  including  high-risk
lones, and  tracing  their  diffusion  [24].  In  this
arlier review,  the  authors  depicted  the  most  com-
on clones  circulating  in  different  geographical
reas and  in  different  present  settings.  The  authors
tated  that  because  the  evolution  of  S.  aureus  will
ontinue,  it  is  important  to  maintain  the  attention
n the  epidemiology  of  S.  aureus  in  the  future  with
 global  view  [24].
mergency Department
and  hygiene  is  essential  in  preventing  nosoco-
ial infections.  The  Emergency  Department  is  an
pen portal  of  entry  for  pathogens  into  the  hospital
ystem, hence  the  important  sentinel  function  of
mergency  Department  personnel  [25].  The  main
bjective  of  this  study  was  to  assess  the  effect
f a  multimodal  improvement  strategy  on  hand
ygiene  compliance  in  the  Emergency  Department
25].  This  was  a  prospective  before-and-after  study
o determine  the  effect  of  a  multimodal  improve-
ent strategy  on  the  compliance  of  hand  hygiene
n the  Emergency  Department  according  to  the  ‘‘My
 Moments’’  of  hand  hygiene  deﬁned  by  the  WHO
nterventions  as  education,  reminders,  and  regu-
ar feedback  on  hand  hygiene  performance  and
ole models  were  planned  during  the  3  intervention
eeks [25].  A  total  of  57  Emergency  Department
urses and  Emergency  Department  physicians  were
bserved  in  this  study;  approximately  1000  oppor-
unities  for  handrubs  were  evaluated  during  the
 intervention  periods.  Hand  hygiene  compliance
ncreased signiﬁcantly  from  baseline  from  18%  to
1% after  the  ﬁrst  intervention  and  stabilized  to  50%
nd 46%  after  the  second  and  third  interventions,
espectively.  Thus,  implementing  a  multimodal
and hygiene  improvement  program  signiﬁcantly
mproved the  compliance  of  Emergency  Depart-
ent personnel  [25].
lostridium difﬁcile infection
ealth  care-acquired  Clostridium  difﬁcile  infec-
ion is  associated  with  adverse  outcomes  at  both
he organization  and  patient  levels.  Factors  that
ncrease  the  risk  for  the  development  of  health
are-acquired Clostridium  difﬁcile  infection  have
een identiﬁed  [26].  The  objectives  of  this  study
ere to  develop  a  predictive  screening  tool  to
dentify patients  at  risk  for  health  care-acquiredPlease  cite  this  article  in  press  as:  Frieri  M,  et  al.  A
http://dx.doi.org/10.1016/j.jiph.2016.08.007
lostridium  difﬁcile  infection  I and  implement  a
undle of  mitigation  interventions  [26].
A predictive  screening  tool  was  developed  based
n risk  factors  identiﬁed  in  the  literature  and
n
v
r
p PRESS
7
alidated  by  retrospective  analysis  of  all  cases
ccurring in  critically  ill  patients  during  2013.  The
ool was  used  to  screen  all  patients  admitted  to
n intensive  care  unit.  Evidence-based  interven-
ions were  implemented  for  patients  identiﬁed
s being  at  high  risk  for  health  care-acquired
lostridium  difﬁcile  infection  [26].  Effectiveness
f the  model  was  measured  by  the  reduction
n the  health  care-acquired  Clostridium  difﬁcile
nfection rate  during  the  intervention  period  com-
ared with  the  pre-intervention  period.  During
he 12-month  intervention  period,  217  high-
isk patients  were  identiﬁed  as  infected  with
lostridium difﬁcile.  Sixty-two  of  these  met  the
xclusion  criteria,  resulting  in  a  study  popula-
ion of  157  patients.  During  the  pre-intervention
hase, 10  cases  occurred.  During  the  12-month
tudy period,  2  cases  were  identiﬁed;  the  reduc-
ion was  statistically  signiﬁcant.  Thus  a strategy
or identifying  patients  at  increased  risk  and  the
mplementation  of  multidisciplinary  risk-mitigation
trategies is  effective  in  reducing  the  incidence
f health  care-acquired  Clostridium  difﬁcile  infec-
ion [26].
Residents  of  long-term  care  facilities  are  at
ncreased risk  for  colonization  and  development
f infections  with  multidrug-resistant  organisms.
his study  was  undertaken  to  determine  the
revalence of  asymptomatic  rectal  colonization
ith Clostridium  difﬁcile  (and  proportion  of
27/NAP1/BI ribotype)  or  carbapenem-resistant
nterobacteriaceae  in  the  long-term  care  facilities
opulation  [27].
Active  surveillance  was  performed  for  C.  difﬁ-
ile and  carbapenem-resistant  Enterobacteriaceae
ectal colonization  of  301  residents  in  a  320-bed
80-bed ventilator  unit),  hospital-afﬁliated  long-
erm care  facility  with  retrospective  chart  review
or patient  demographics  and  potential  risk  factors
27]. Over  40%  of  patients  had  airway  ventilation
nd received  enteral  feeding.  One-third  of  these
atients  had  prior  C.  difﬁcile-associated  infection.
symptomatic  rectal  colonization  with  C. difﬁcile
ccurred  in  58  patients  (19.3%,  one-half  with
AP1+),  carbapenem-resistant  Enterobacteriaceae
ccurred in  57  patients  (18.9%),  and  both  occurred
n 17  patients.  Recent  carbapenem-resistant
nterobacteriaceae  was  signiﬁcantly  associated
ith an  increased  risk  of  C.  difﬁcile  ±  carbapenem-
esistant Enterobacteriaceae  colonization.
ultivariate  logistic  regression  analysis  revealed
he presence  of  tracheostomy  collar  to  be  sig-ntibiotic  resistance.  J  Infect  Public  Health  (2016),
iﬁcant for  C.  difﬁcile  colonization,  mechanical
entilation to  be  signiﬁcant  for  carbapenem-
esistant  Enterobacteriaceae  colonization,  and
rior Clostridium  difﬁcile  infection  to  be  signiﬁcant
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for  both  C.  difﬁcile  and  carbapenem-resistant
Enterobacteriaceae  colonization  [27].
Thus, the  strong  association  of  C.  difﬁcile
or carbapenem-resistant  Enterobacteriaceae  col-
onization  with  disruption  of  normal  ﬂora  by
mechanical ventilation,  enteral  feeds,  and  prior
Clostridium  difﬁcile  infection  carries  important
implications for  infection  control  intervention  in
this population  [27].
Vancomycin-resistant enterococci
Between  2013  and  2014,  a  vancomycin-resistant
enterococci  (VRE)  outbreak  occurred  in  a teaching
hospital in  France.  The  outbreak  was  possibly  due  to
the lack  of  implementation  of  recommended  con-
trol measures.  The  aim  of  this  study  was  to  identify
the effect  of  the  lack  of  adherence  to  control  meas-
ures for  prevention  of  VRE  acquisition  in  contact
patients taking  into  account  individual  risk  factors
[28].  Contact  patients  with  VRE  acquisition  were
compared  to  patients  without  VRE  acquisition  in
terms of  institutional  characteristics  and  risk  fac-
tors. Between  December  2013  and  February  2014,
282 contact  patients  were  included  in  the  study.
The prevalence  of  VRE  acquisition  was  6.4%  and
signiﬁcant risk  factors  for  VRE  acquisition  accord-
ing to  logistic  regression  analysis  included  lack  of
isolation,  hospitalization  in  the  same  hospital  unit
as a  VRE  carrier  patient  and  lack  of  isolation,  hos-
pitalization  in  a  speciﬁc  unit,  age,  hemodialysis,
central venous  catheter  and  surgery  [28]  Antibiotic
use  was  a  signiﬁcant  risk  factor  for  VRE  acquisi-
tion using  univariate  analysis.  The  ﬁndings  of  these
authors conﬁrmed  that  the  factors  focused  on  by
the study  (lack  of  isolation  and  dedicated  unit)  had
a signiﬁcant  effect  on  VRE  acquisition  as  patient-
associated factors.  It  highlighted  the  importance  of
observance  of  the  guidelines  [28].
Infections  attributable  to  VRE  have  become
increasingly  prevalent  over  the  past  decade.
Prompt identiﬁcation  of  colonized  patients  com-
bined with  effective  multifaceted  infection  control
practices  can  reduce  transmission  of  VRE  and  aid
in preventing  hospital-acquired  infections  [29].  The
clinical microbiology  laboratory  is  being  asked  to
support infection  control  efforts  through  early  iden-
tiﬁcation  of  potential  patient  or  environmental
reservoirs.  This  review  discussed  the  factors  that
contribute  to  the  increase  in  VRE  as  an  impor-
tant healthcare-associated  pathogen,  the  utility  of
laboratory screening  and  various  infection  controlPlease  cite  this  article  in  press  as:  Frieri  M,  et  al.  A
http://dx.doi.org/10.1016/j.jiph.2016.08.007
strategies  and  the  available  laboratory  methods  to
identify VRE  in  clinical  specimens  [29].
VRE infections  are  a  public  health  threat
associated  with  increased  patient  mortality  and
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ealthcare  costs.  Antibiotic  usage,  particularly  of
ephalosporins,  has  been  associated  with  VRE  col-
nization  and  VRE  bloodstream  infections.  These
uthors  examined  the  relationship  between  antimi-
robial usage  and  incident  VRE  colonization  at  the
ndividual patient  level  [30]. Prospective  weekly
urveillance  was  undertaken  for  incident  VRE  col-
nization  was  deﬁned  by  negative  admission  but
ositive surveillance  swab  in  a medical  intensive
are unit  over  a 17-month  period  [30].  Ninety-
ix percent  of  admitted  patients  were  swabbed
ithin 24  h  of  intensive  care  unit  arrival;  of  the
80 patients  in  the  ICU  long  enough  for  weekly
urveillance, 22%  developed  incident  VRE  colo-
ization.  Incident  colonization  was  associated  with
ale gender,  more  previous  hospital  admissions,
onger previous  hospital  stay,  and  the  use  of
efepime/ceftazidime,  ﬂuconazole,  azithromycin,
nd metronidazole  [30]. After  controlling  for  demo-
raphic and  clinical  covariates,  metronidazole  was
he only  antibiotic  independently  associated  with
ncident VRE  colonization.  Their  ﬁndings  suggest
hat risk  of incident  VRE  colonization  differs
etween individual  antibiotic  agents  and  support
he possibility  that  antimicrobial  stewardship  may
mpact VRE  colonization  and  infection  [30].
These authors  reported  an  outbreak  of  van-
omycin variable  vanA+ enterococci  (VVE)  able
o escape  phenotypic  detection  by  current  guide-
ines,  and  demonstrate  the  molecular  mechanisms
or in  vivo  switching  into  vancomycin  resistance
nd horizontal  spread  of  the  vanA  cluster  [31].
orty-eight  vanA+ Enterococcus  faecium  and  one
nterococcus  faecalis  isolates  were  analyzed  for
lonality with  PFGE  and  their  vanA  gene  cluster
omposition assessed  by  PCR  and  whole  genome
equencing of six  isolates.  The  VVE  had  insertion
f IS1542  between  orf2  and  vanR  that  attenuated
he expression  of  the  vanHAX  activator  coded  by
anRS. Growth  of  susceptible  VVE  occurred  after
4—72 h  of  exposure  to  vancomycin  due  to  exci-
ion of  the  ISL3-family  element  [31].  The  vanA  gene
luster was  located  on  a  transferable  broad  host-
ange plasmid  also  detected  in  outbreak  isolates
ith different  pulsotypes  as  well  as  one  E.  fae-
alis. Horizontally  transferable  silenced  vanA  able
o escape  detection  and  revert  into  resistance  dur-
ng vancomycin  therapy  represents  a  new  challenge
n the  clinic.  Genotypic  testing  of  invasive  VSE  by
anA-PCR  is  advised  [31].
ontrol in the Emergency Departmentntibiotic  resistance.  J  Infect  Public  Health  (2016),
 prospective  observational  study  was  conducted  at
 university-afﬁliated  urban  teaching  hospital  and
evel-1 trauma  and  burn  center.  All  adult  patients
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ntibiotic  resistance  
ho  triggered  a  Code  Sepsis  in  the  Emergency
epartment  between  January  2010  and  December
011 were  included  [32]. Hospital  mortality  and
ospital  loss  of  stay  of  sepsis  are  similar  to  those
eported in  other  observational  studies.  This  study
onﬁrmed  a  decline  in  the  mortality  of  sepsis  pre-
icted by  earlier  longitudinal  studies  and  should
rompt a resurgence  in  epidemiological  research  of
epsis syndromes  in  the  United  States  [32].
How closely  physicians  follow  Infectious  Disease
ociety of  America  guidelines  is  unknown,  particu-
arly in  the  Emergency  Department  observation  unit
here increasing  numbers  of  patients  are  treated
or these  infections.  The  objectives  of  this  paper
ere to  describe  (1)  the  antibiotic  treatment  pat-
erns in  the  Emergency  Department  observation
nit; (2)  physicians’  adherence  to  the  Infectious
isease Society  of  America  guidelines;  and  (3)  fac-
ors that  inﬂuence  physicians’  prescribing  practices
33].  This  paper  showed  that  physician  antibiotic
rescribing practices  demonstrated  poor  adherence
o Infectious  Disease  Society  of  America  guidelines
nd were  inﬂuenced  by  the  patient’s  age  and  sex.
tandardized  antibiotic  protocols  for  the  treatment
f skin  and  soft  tissue  infections  to  Infectious  Dis-
ase Society  of  America  guidelines  is  unknown,
articularly in  the  Emergency  Department  obser-
ation  unit,  which  would  minimize  physician
ias [33].
The increase  in  antibiotic-resistant  pathogens  is
elieved to  have  inﬂuenced  the  Emergency  Depart-
ent epidemiology  and  management  of  infectious
iseases since  2000  [34].
Data from  the  National  Hospital  Ambulatory  Med-
cal Care  Survey  from  2000  to  2010  were  used
o examine  temporal  trends  in  the  incidence  of
nfectious  diseases  presenting  to  the  Emergency
epartment.  Outcome  measures  included  national
isit rates,  visit  proportions,  and  antimicrobial
rescriptions  for  all  infectious  disease  primary  diag-
oses, as  well  as  for  speciﬁc  organ  systems  of
nterest such  as  the  respiratory  tract,  skin/soft  tis-
ue, and  urinary  tract  [34].
An infectious  disease-related  primary  diagnosis
as given  in  18.3%  of  all  Emergency  Department
isits during  the  study  period.  Management  of
kin and  soft  tissue  infections  shifted  from  pre-
ominant use  of  cephalosporins  to  sulfonamides.
or UTIs,  quinolones  were  most  commonly  pre-
cribed,  with  an  increasing  use  of  third-generation
ephalosporins  [34]. Antibiotics  were  more  fre-
uently  prescribed  to  patients  who  were  white.Please  cite  this  article  in  press  as:  Frieri  M,  et  al.  A
http://dx.doi.org/10.1016/j.jiph.2016.08.007
hus, the  changing  epidemiology  of  infectious  dis-
ases diagnosed  in  US  Emergency  Departments
eﬂects national  trends  in  emerging  pathogens  and
rug resistance.  Broad-spectrum  antibiotics  are PRESS
9
eing  prescribed  at  increasing  rates.  There  are
igniﬁcant  demographic  disparities  in  nationwide
ntibiotic prescription  practices  [34].
onclusion
ntimicrobial  resistance  in  bacterial  pathogens  is
 signiﬁcant  challenge  that  has  a  high  morbid-
ty and  mortality.  Multidrug  resistant  patterns  in
ram-positive  and  -negative  bacteria  are  difﬁcult
o treat  and  may  even  be  untreatable  with  con-
entional  antibiotics.  Challenges  associated  with
acterial infection  and  associated  diseases  are  due
o the  current  shortage  of  effective  therapies,
ack of  successful  prevention  measures,  and  lack
f new  antibiotics,  which  require  development  of
ovel treatment  options  and  alternative  antimicro-
ial therapies.  Bioﬁlms  are  involved  in  multidrug
esistance and  can  present  challenges  for  infection
ontrol.  Virulence,  S.  aureus,  Clostridium  difﬁcile
nfection  vancomycin-resistant  enterococci,  and
ontrol in  the  Emergency  Department  were  dis-
ussed.
unding
o  funding  sources.
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